In the world of speculative biotech, one company that is clearly on the cutting edge is Advanced Cell Technology (OTCQB:ACTC). This biotechnology company is focused on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. In terms of ongoing clinical trials, the company's main focus revolves around its three macular degeneration trials, two in the U.S. and one in Europe.
As with any small biotech company, like ACT, it takes a great amount of time and research to get enough meaningful data to see if one should invest. Reading SEC filings, listening to conference calls, and viewing corporate presentations provides a great deal of insight, but that is not...
Only subscribers can access this article, which is part of the PRO research library covering 3,602 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: